GlassScriptPhysician profile
Thomas J Mckenna
NPI 1063724490
$14,940.52
in general payments reported to CMS, 2019-2025
46 companies · $3,033 in 2025
The $3,033 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,679 · 2020: $986 · 2021: $1,657 · 2022: $2,063 · 2023: $2,010 · 2024: $2,513 · 2025: $3,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,540 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,539.90 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,740.78 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,675.55 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,353.52 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $877.89 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $705.15 | 2019-2025 | |
| Celgene Corporation | $609.46 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $441.38 | 2019-2025 | Linzess |
| Qol Medical, LLC | $401.60 | 2019-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $340.45 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $317.47 | 2022-2025 | Dupixent |
| Ucb, INC. | $284.60 | 2019-2020 | |
| Daiichi Sankyo INC. | $266.70 | 2019-2025 | Injectafer |
| Gilead Sciences, INC. | $264.71 | 2019-2025 | Epclusa |
| Lilly USA, LLC | $237.75 | 2024-2025 | Omvoh |
| Genzyme Corporation | $231.62 | 2023-2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $206.19 | 2019 | |
| Boston Scientific Corporation | $167.10 | 2019-2023 | Wallflex Duodenal |
| Ardelyx, INC. | $166.34 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $147.76 | 2019-2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $131.79 | 2020-2023 | |
| Amgen INC. | $124.75 | 2019-2023 | Amjevita, Avsola |
| Ipsen Biopharmaceuticals, INC | $115.44 | 2025 | Iqirvo |
| Janssen Scientific Affairs, LLC | $112.76 | 2019 | |
| Phathom Pharmaceuticals, INC. | $105.38 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $103.31 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $92.67 | 2019-2024 | Ocaliva |
| Braintree Laboratories, INC. | $87.96 | 2022-2024 | Suflave, Sutab |
| Bayer Healthcare Pharmaceuticals INC. | $84.89 | 2021 | |
| Enterra Medical, INC. | $58.62 | 2022 | |
| Redhill Biopharma INC. | $54.48 | 2020-2022 | |
| Celltrion USA INC. | $47.72 | 2024 | Vegzelma |
| Romark Laboratories, Lc | $46.94 | 2019 | |
| Shire North American Group INC | $43.72 | 2019 | |
| Shionogi INC | $37.84 | 2019 | |
| Novo Nordisk INC | $29.16 | 2025 | Wegovy |
| Vivus LLC | $28.13 | 2019 | |
| Portola Pharmaceuticals, LLC | $26.04 | 2020 | |
| Kerecis Limited | $25.71 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Allergan, INC. | $23.98 | 2019 | |
| Organon LLC | $21.14 | 2025 | Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.07 | 2024 | Cyltezo |
| Intra-Sana Laboratories | $20.61 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Aimmune Therapeutics, INC. | $18.04 | 2025 | Zenpep |
| Sandoz INC. | $15.84 | 2024 | Hyrimoz |
| Alnylam Pharmaceuticals INC. | $13.52 | 2020 | |
| Albireo Pharma, INC. | $12.99 | 2023 | Bylvay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mckenna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.